Synapse - Works

Results (15762)

Outcomes and management of SARS-CoV2 omicron variant in recipients of hematopoietic cell transplantation (HCT) and CAR-T therapy

Meeting Abstract

Infante, M. S.; DeWolf, S.; Tamari, R.; Dahi, P. B.; Lee, Y. J.; Politikos, I.; Barker, J. N.; Babady, N. E.; Ramanathan, L.; Seo, S.; more...
Blood (2022)

Fulltext@MSK | Save

Predictors and implications of renal injury in large cell lymphoma patients receiving CD19 CAR T cell therapy

Meeting Abstract

Boardman, A. P.; Gutgarts, V.; Flynn, J. R.; Devlin, S. M.; Tomas, A. A.; Fein, J. A.; Slingerland, J.; Parascondola, A.; Lin, R. J.; Scordo, M.; more...
Blood (2022)

Fulltext@MSK | Save

A phase 1 first-in-human study of Abbv-383, a BCMA x CD3 bispecific T-cell-redirecting antibody, as monotherapy in patients with relapsed/refractory multiple myeloma

Meeting Abstract

Voorhees, P. M.; D'Souza, A.; Weisel, K.; Hurd, D. D.; Teipel, R.; Chung, A.; Rodriguez, C.; Tuchman, S. A.; Korde, N.; Safah, H.; more...
Blood (2022)

Fulltext@MSK | Save

A phase 2 trial of colesevelam for lenalidomide-associated diarrhea

Meeting Abstract

Hultcrantz, M.; Hassoun, H.; Korde, N.; Mailankody, S.; Shekarkhand, T.; Burge, M.; Maclachlan, K. H.; Patel, D.; Shah, U. A.; Chung, D. J.; more...
Blood (2022)

Fulltext@MSK | Save

Stem cell mobilization characteristics for transplant eligible patients with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib, lenalidomide, dexamethasone, and daratumumab (KRd-Dara)

Meeting Abstract

Bhutani, M.; Robinson, M.; Atrash, S.; Watts, N.; Paul, B.; Chhabra, S.; Korde, N.; Begic, X.; Foureau, D. M.; Chung, D. J.; more...
Blood (2022)

Fulltext@MSK | Save

Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs): Updated results from a phase I/II study

Meeting Abstract

Budde, E. L.; Bartlett, N. L.; Giri, P.; Schuster, S. J.; Assouline, S.; Yoon, S. S.; Fay, K.; Matasar, M. J.; Gutierrez, N. C.; Marlton, P.; more...
Blood (2022)

Fulltext@MSK | Save

Identifying primary refractory disease and early relapses in peripheral T-cell lymphoma using baseline characteristics, minimal residual disease, and mutational profiling

Meeting Abstract

Stuver, R.; Haynie, H.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Mazloom, A.; Moskowitz, A. J.; Drill, E.; Horwitz, S. M.
Blood (2022)

Fulltext@MSK | Save

Outcomes for patients with relapsed and refractory peripheral T-cell lymphoma in the 21st century by relapse status, salvage therapy, and receipt of allogeneic transplant

Meeting Abstract

Stuver, R.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Sauter, C. S.; Scordo, M.; Shah, G. L.; Moskowitz, A. J.; Horwitz, S. M.
Blood (2022)

Fulltext@MSK | Save

Emapalumab for malignancy-associated hemophagocytic lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center experience

Meeting Abstract

Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Chang, T.; Galasso, N.; Stuver, R.; Khan, N.; Salles, G.; Moskowitz, A. J.; Vardhana, S.; more...
Blood (2022)

Fulltext@MSK | Save

Population pharmacokinetics and exposure-response analyses from Phase I-III studies support copanlisib dose selection in relapsed indolent non-Hodgkin lymphoma

Meeting Abstract

Moss, J.; Garmann, D.; Austin, R.; Hiemeyer, F.; Matasar, M. J.; Zinzani, P. L.; Beckert, V.; Soler, L. M.; Childs, B. H.; Morcos, P. N.
Blood (2022)

Fulltext@MSK | Save